Normal Volunteers, Patients, or Hybrids? Should We Build the Bridge Slowly to Cross It Quickly?

This webinar will cover the following orphan drug topics: How to adjudicate multiple stakeholder perspectives in first-in-human studies with constrained resources; More dose levels, fewer participants, and the importance of bioanalysis.

Authors:

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer

Sherilyn Adcock, RPh, PhD

Chief Scientific Officer, Early Phase Development